Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations.
Many plant polyphenolic compounds have been shown to have cancer-preventing activities in laboratory studies. For example, tea and tea preparations have been shown to inhibit tumorigenesis in a variety of animal models of carcinogenesis, involving organ sites such as the skin, lungs, oral cavity, esophagus, stomach, liver, pancreas, small intestine, colon, and prostate. In some of these models, inhibitory activity was demonstrated when tea was administered during the initiation, promotion, or progression stage of carcinogenesis. The cancer-preventing activities of these and other polyphenols, such as curcumin, genistein, and quercetin, are reviewed. In studies in vitro, many of these compounds have been shown to affect signal transduction pathways, leading to inhibition of cell growth and transformation, enhanced apoptosis, reduced invasive behavior, and slowed angiogenesis. However, the concentrations used in cell culture studies were much higher than those found in vivo. If we propose mechanisms for cancer prevention on the basis of cell line experiments, then these activities must be demonstrated in vivo. The bioavailability, ie, tissue and cellular concentrations, of dietary polyphenols is a determining factor in their cancer-preventing activity in vivo. For example, compounds such as curcumin are effective when applied topically to the skin or administered orally to affect the colon but are not effective in internal organs such as the lungs. More in-depth studies on bioavailability should facilitate correlation of mechanisms determined in vitro with in vivo situations, increase our understanding of dose-response relationships, and facilitate extrapolation of results from animal studies to human situations.
Lambert
Joshua D
JD
Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, USA.
Hong
Jungil
J
Yang
Guang-Yu
GY
Liao
Jie
J
Yang
Chung S
CS
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D006224:Cricetinae; D003474:Curcumin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004032:Diet; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019833:Genistein / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051379:Mice; D009374:Neoplasms, Experimental / Q000517:prevention & control*; D011794:Quercetin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013662:Tea
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D013662:Tea; D011794:Quercetin; D019833:Genistein; D003474:Curcumin